Groups want FDA to leave Avastin alone

Share this article:
Two breast cancer treatment advocacy groups have written to FDA asking that the agency refrain from changing the approved labeling for Genentech's Avastin. The letter from Komen for the Cure and Ovarian Cancer National Alliance is in response to an FDA advisory panel recommendation that the agency revoke an accelerated approval indication for Avastin for combination use with paclitaxel for treating previously untreated advanced HER2-negative breast cancer.

The panel voted 12 to 1 in favor of removing the indication from Avastin's approved uses, with panel members agreeing that two post-approval studies did not show the therapy's effect to be clinically significant. They acted after considering an FDA staff briefing that said the “risk-benefit ratio when added to the standard chemotherapeutic regimens…may not be considered favorable.”

“We recognize the benefits of Avastin overall are modest for women with metastatic breast cancer,” said ambassador Nancy G. Brinker, Komen's founder and CEO, in the letter to FDA. “However, we do know that for some women, Avastin offers a greater than modest benefit. We hope that this decision will not restrict access to Avastin to all patients.”

The letter argued that many doctors report patients taking Avastin enjoy “better than modest results,” and that the decision to use Avastin should be made between a woman and her doctor.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?